AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: DELMAR PHARMACEUTICALS, INC., a Nevada corporation; ADGERO ACQUISITION CORP., a Delaware corporation; and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC. a Delaware corporation Dated as of June 9, 2020Merger Agreement • June 10th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 9, 2020, by and among DELMAR PHARMACEUTICALS, INC., a Nevada corporation (“Parent”), ADGERO ACQUISITION CORP., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”). Parent, Merger Sub and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Exhibit A.
STOCKHOLDER SUPPORT AGREEMENTStockholder Support Agreement • June 10th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of [●], 2020, by and among Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each of the undersigned stockholders (each, a “Holder”) of DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Parent”).
